WO2011043519A3 - Sulfonamide derivatives as serotonin receptor antagonist and serotonin reuptake inhibitor - Google Patents
Sulfonamide derivatives as serotonin receptor antagonist and serotonin reuptake inhibitor Download PDFInfo
- Publication number
- WO2011043519A3 WO2011043519A3 PCT/KR2010/001633 KR2010001633W WO2011043519A3 WO 2011043519 A3 WO2011043519 A3 WO 2011043519A3 KR 2010001633 W KR2010001633 W KR 2010001633W WO 2011043519 A3 WO2011043519 A3 WO 2011043519A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- serotonin
- sulfonamide derivatives
- receptor antagonist
- reuptake inhibitor
- serotonin reuptake
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to sulfonamide derivatives as a serotonin receptor antagonist and serotonin reuptake inhibitor and a pharmaceutically acceptable salt thereof. The sulfonamide derivatives have serotonin 5-HT2A and 5-HT2C receptor antagonizing and serotonin reuptake inhibiting functions, and thus may be efficiently applied to a CNS-related disease such as depression, obesity, psychosis, schizophrenia, suicidal tendency, anxiety, obsessional neurosis, migraine, appetite disorders, sleep disorders, stroke, and withdrawal symptoms caused by drug abuse.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090096094A KR101152659B1 (en) | 2009-10-09 | 2009-10-09 | Novel sulfonamide compounds as serotonin receptor antagonists and serotonin transporter inhibitor |
KR10-2009-0096094 | 2009-10-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011043519A2 WO2011043519A2 (en) | 2011-04-14 |
WO2011043519A3 true WO2011043519A3 (en) | 2011-10-20 |
Family
ID=43857239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/001633 WO2011043519A2 (en) | 2009-10-09 | 2010-03-17 | Sulfonamide derivatives as serotonin receptor antagonist and serotonin reuptake inhibitor |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101152659B1 (en) |
WO (1) | WO2011043519A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL395470A1 (en) * | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Alicyclic amines sulfonamide derivatives for the treatment of diseases of the central nervous system |
FR3030516B1 (en) * | 2014-12-19 | 2019-12-27 | Galderma Research & Development | BICYCLE SULFONAMIDE DERIVATIVES AS INVERTED AGONISTS OF THE ORPHAN GAMMA RECEPTOR ASSOCIATED WITH ROR GAMMA (T) RETINOIDS |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996036595A1 (en) * | 1995-05-19 | 1996-11-21 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
US20080200461A1 (en) * | 2007-02-20 | 2008-08-21 | Cropsolution, Inc. | Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0407180A (en) * | 2003-02-14 | 2006-02-07 | Lilly Co Eli | Compound, pharmaceutical composition, methods for modulating a peroxisome proliferator-activated receptor, for treating or preventing a disease or condition, for lowering blood glucose in a mammal, for treating or preventing diabetes mellitus, cardiovascular disease, and syndrome x in a mammal. , and, use of a compound |
US20060025445A1 (en) | 2004-08-02 | 2006-02-02 | Xiang Jason S | 11-Beta HSD1 inhibitors |
CN101426788A (en) | 2006-04-20 | 2009-05-06 | 詹森药业有限公司 | Substituted pyrazinone derivatives for use as a medicine |
-
2009
- 2009-10-09 KR KR1020090096094A patent/KR101152659B1/en not_active IP Right Cessation
-
2010
- 2010-03-17 WO PCT/KR2010/001633 patent/WO2011043519A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996036595A1 (en) * | 1995-05-19 | 1996-11-21 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
US20080200461A1 (en) * | 2007-02-20 | 2008-08-21 | Cropsolution, Inc. | Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
KR101152659B1 (en) | 2012-06-15 |
WO2011043519A2 (en) | 2011-04-14 |
KR20110038903A (en) | 2011-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2020042I1 (en) | Entrektinib or isomers, tautomers, or pharmaceutically acceptable salts thereof | |
MX2007004794A (en) | Thienopyridines as allosteric potentiators of the m4 muscarinic receptor. | |
IL214049A0 (en) | Agonists and antagonists of the s1p5 receptor, and methods of uses thereof | |
WO2008012622A3 (en) | Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor | |
ZA200706354B (en) | Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses | |
WO2007150025A3 (en) | Purinone derivatives as hm74a agonists | |
WO2010148207A3 (en) | Processes for the preparation of 5-ht2c receptor agonists | |
WO2007119214A3 (en) | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis | |
WO2008087491A8 (en) | Method for treating or preventing symptoms of hormonal variations | |
PT2364142T (en) | Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto | |
WO2007150026A3 (en) | Purinone derivatives as hm74a agonists | |
BRPI0925343A2 (en) | Compound, pharmaceutical composition, and prophylactic or therapeutic drug | |
WO2010018549A3 (en) | Therapeutic compositions containing macitentan | |
CL2007003637A1 (en) | PROCEDURE FOR THE PREPARATION OF BENZIMIDA PIPERACINILO AND DIAZEPANILO DERIVATIVES USEFUL FOR THE TREATMENT OF DISORDERS AND INTERMEDIATE CONDITIONS BY A HISTAMINE RECEIVER. | |
UA107334C2 (en) | Alkaloid aminoester derivatives and their drug compositions | |
MX353209B (en) | D2 ANTAGONISTS, METHODS OF SYNTHESIS and METHODS OF USE. | |
MX2011008413A (en) | Enhanced migraine treatments based on ghrelin mimetics. | |
IL196094A0 (en) | Cyclopropyl amine derivatives as histamin h3 receptor modulators | |
WO2010120695A3 (en) | 5-ht4 receptor agonist compounds for treatment of cognitive disorders | |
IL201923A0 (en) | Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | |
WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
WO2009118765A8 (en) | Novel monoamine re-uptake inhibitor | |
WO2011043519A3 (en) | Sulfonamide derivatives as serotonin receptor antagonist and serotonin reuptake inhibitor | |
WO2011008666A3 (en) | 3-phenoxymethylpyrrolidine compounds | |
WO2013036015A3 (en) | Azetidine derivative and antidepressant composition containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10822164 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC - FORM 1205A (16.07.2012) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10822164 Country of ref document: EP Kind code of ref document: A2 |